These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 35285503)

  • 1. Safety and Efficacy of Bis-Glyceryl Ascorbate as Prophylaxis for Hand-Foot Skin Reaction: A Single-Arm, Open-Label Phase I/II Study (DGA Study).
    Yamamoto K; Nishiyama S; Kunisada M; Iida M; Ito T; Ioroi T; Makimoto H; Omura T; Harada K; Fujisawa M; Nishigori C; Yano I
    Oncologist; 2022 May; 27(5):e384-e392. PubMed ID: 35285503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and Efficacy of Bis-Glyceryl Ascorbate (Amitose DGA) to Prevent Hand-Foot Skin Reaction in Patients With Renal Cell Carcinoma Receiving Sunitinib Therapy: Protocol for a Phase I/II, Uncontrolled, Single-Arm, Open-Label Trial.
    Yamamoto K; Ioroi T; Harada K; Nishiyama S; Nishigori C; Yano I
    JMIR Res Protoc; 2019 Aug; 8(8):e14636. PubMed ID: 31407671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Effect of Topical Urea for Secondary Prophylaxis of Hand Foot Skin Reaction in Renal Cell Cancer Patients on Sunitinib Therapy.
    Naeem SS; Gupta P; Sahoo RK; Kumar VL; Velpandian T; Singh A; Batra A; Pramanik R; Rastogi S; Srivastava S
    Clin Genitourin Cancer; 2024 Jun; 22(3):102073. PubMed ID: 38626661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: a meta-analysis.
    Chu D; Lacouture ME; Weiner E; Wu S
    Clin Genitourin Cancer; 2009 Jan; 7(1):11-9. PubMed ID: 19213662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anlotinib Versus Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial.
    Zhou AP; Bai Y; Song Y; Luo H; Ren XB; Wang X; Shi B; Fu C; Cheng Y; Liu J; Qin S; Li J; Li H; Bai X; Ye D; Wang J; Ma J
    Oncologist; 2019 Aug; 24(8):e702-e708. PubMed ID: 30902918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized multicenter phase II trial on the efficacy of a hydrocolloid dressing containing ceramide with a low-friction external surface for hand-foot skin reaction caused by sorafenib in patients with renal cell carcinoma.
    Shinohara N; Nonomura N; Eto M; Kimura G; Minami H; Tokunaga S; Naito S
    Ann Oncol; 2014 Feb; 25(2):472-6. PubMed ID: 24351402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis.
    Josephs D; Hutson TE; Cowey CL; Pickering LM; Larkin JM; Gore ME; Van Hemelrijck M; McDermott DF; Powles T; Chowdhury P; Karapetis C; Harper PG; Choueiri TK; Chowdhury S
    BJU Int; 2011 Oct; 108(8):1279-83. PubMed ID: 21244613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of urea cream on sorafenib-associated hand-foot skin reaction in patients with hepatocellular carcinoma: A multicenter, randomised, double-blind controlled study.
    Lee YS; Jung YK; Kim JH; Cho SB; Kim DY; Kim MY; Kim HJ; Seo YS; Yoon KT; Hong YM; Lee JH; Lee HW; Yim HJ; Jang BK; Jang ES; Jang JY; Hwang SY
    Eur J Cancer; 2020 Nov; 140():19-27. PubMed ID: 33039810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma.
    Escudier B; Roigas J; Gillessen S; Harmenberg U; Srinivas S; Mulder SF; Fountzilas G; Peschel C; Flodgren P; Maneval EC; Chen I; Vogelzang NJ
    J Clin Oncol; 2009 Sep; 27(25):4068-75. PubMed ID: 19652072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma.
    Ren Z; Zhu K; Kang H; Lu M; Qu Z; Lu L; Song T; Zhou W; Wang H; Yang W; Wang X; Yang Y; Shi L; Bai Y; Guo X; Ye SL
    J Clin Oncol; 2015 Mar; 33(8):894-900. PubMed ID: 25667293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of aluminum chloride in severe regorafenib-associated hand-foot skin reactions: a single-arm trial.
    Nishizawa A; Shinozaki E; Wakatsuki T; Satoh T; Yamazaki N; Oyamada S; Ariyoshi K; Kihara K; Tsuboi M; Yamaguchi K
    BMC Cancer; 2023 May; 23(1):401. PubMed ID: 37142953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomised Phase II study comparing alternating cycles of sunitinib and everolimus vs standard sequential administration in first-line metastatic renal carcinoma (SUNRISES study).
    Rodriguez-Vida A; Bamias A; Esteban E; Saez MI; Lopez-Brea M; Castellano D; Caballero C; Gonzalez-Larriba JL; Calvo E; Macia S; Ravaud A; Bellmunt J
    BJU Int; 2020 Nov; 126(5):559-567. PubMed ID: 32654362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic Effect of Anti-inflammatory Tripeptide Cream in Hand-Foot Syndrome/Skin Reaction Related to Anticancer Drugs: A Randomized, Double-Blind, Placebo-Controlled Pilot Trial.
    Yang Y; Hahn JH; Kim MS; Jo M; Lee YP; Kim H; Kim HK; Kwon J; Lee KH; Han HS
    Cancer Res Treat; 2024 Oct; 56(4):1050-1057. PubMed ID: 38853540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Association between hand-foot skin reaction and effectiveness of vascular endothelial growth factor receptor tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma].
    Song Y; Du CX; Zhang W; Sun YK; Yang L; Cui CX; Yihebali C; Zhou AP; Wang JW; Sun Y
    Zhonghua Yi Xue Za Zhi; 2016 Sep; 96(34):2717-2721. PubMed ID: 27667104
    [No Abstract]   [Full Text] [Related]  

  • 15. SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer.
    Eichelberg C; Vervenne WL; De Santis M; Fischer von Weikersthal L; Goebell PJ; Lerchenmüller C; Zimmermann U; Bos MM; Freier W; Schirrmacher-Memmel S; Staehler M; Pahernik S; Los M; Schenck M; Flörcken A; van Arkel C; Hauswald K; Indorf M; Gottstein D; Michel MS
    Eur Urol; 2015 Nov; 68(5):837-47. PubMed ID: 25952317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.
    Lee WJ; Lee JL; Chang SE; Lee MW; Kang YK; Choi JH; Moon KC; Koh JK
    Br J Dermatol; 2009 Nov; 161(5):1045-51. PubMed ID: 19558553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.
    Motzer RJ; Rini BI; McDermott DF; Arén Frontera O; Hammers HJ; Carducci MA; Salman P; Escudier B; Beuselinck B; Amin A; Porta C; George S; Neiman V; Bracarda S; Tykodi SS; Barthélémy P; Leibowitz-Amit R; Plimack ER; Oosting SF; Redman B; Melichar B; Powles T; Nathan P; Oudard S; Pook D; Choueiri TK; Donskov F; Grimm MO; Gurney H; Heng DYC; Kollmannsberger CK; Harrison MR; Tomita Y; Duran I; Grünwald V; McHenry MB; Mekan S; Tannir NM;
    Lancet Oncol; 2019 Oct; 20(10):1370-1385. PubMed ID: 31427204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of sunitinib and SU12662 on dermatological toxicities in metastatic renal cell carcinoma patients: in vitro, in vivo, and outcomes investigation.
    Teo YL; Chong XJ; Chue XP; Chau NM; Tan MH; Kanesvaran R; Wee HL; Ho HK; Chan A
    Cancer Chemother Pharmacol; 2014 Feb; 73(2):381-8. PubMed ID: 24306119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
    Cai W; Yuan YC; Li MY; Kong W; Dong BJ; Chen YH; Zhang J; Xue W; Huang YR; Zhou LX; Huang JW
    Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):384-389. PubMed ID: 29860767
    [No Abstract]   [Full Text] [Related]  

  • 20. Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma.
    Barrios CH; Hernandez-Barajas D; Brown MP; Lee SH; Fein L; Liu JH; Hariharan S; Martell BA; Yuan J; Bello A; Wang Z; Mundayat R; Rha SY
    Cancer; 2012 Mar; 118(5):1252-9. PubMed ID: 21898376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.